Home Ingredients WokVel® (Boswellia Serrata Extract — Pharmanza)
Joint Health

WokVel® (Boswellia Serrata Extract — Pharmanza)

Boswellia serrata
Evidence Level
Limited
1 Clinical Trial
6 Documented Benefits
2/5 Evidence Score

WokVel® is the branded standardized boswellia serrata extract from Pharmanza Herbal (India) — a boswellia form whose own clinical testing is limited to one small, older placebo-controlled knee osteoarthritis trial; the broader boswellia research for joint and inflammatory conditions comes mostly from other extracts and brands. Standardized to consistent boswellic acid content with quality control supporting reproducible clinical effects. Distinct from AprèsFlex®/Aflapin® (also a branded boswellia with different standardization focus on AKBA). The best WokVel-specific human evidence is a single small study: an 8-week randomized crossover trial in 30 knee osteoarthritis patients (Kimmatkar 2003) reporting less knee pain, greater knee flexion and longer walking distance. Wider osteoarthritis support for Boswellia serrata comes from other extracts and brands, not from WokVel itself. The honest framing: WokVel is a quality-controlled boswellia, but its own clinical testing is limited to one small older knee osteoarthritis trial. The osteoarthritis trials most often cited for boswellia used other extracts, so the brand premium buys manufacturing consistency, not a larger or brand-specific evidence base. Generic high-AKBA boswellia extracts (≥20% AKBA) produce similar mechanism; WokVel® offers manufacturing assurance and trial-grade quality.

Studied Dose 333 mg three times daily (1,000 mg/day total) or equivalent split doses.
Active Compound WokVel® standardized boswellia serrata extract (Pharmanza); standardized boswellic acid content.

Benefits

Osteoarthritis pain and function trial (one small crossover study)

A single small randomized crossover trial of a Pharmanza Boswellia serrata extract (Kimmatkar 2003, 30 knee osteoarthritis patients, 8 weeks per arm) reported reduced knee pain and improved function. This is the main WokVel-specific human trial, and on its own it does not show the branded form works better than generic boswellia.

Supported by Trial 1

Standardized boswellic acid content

WokVel® provides reproducible boswellic acid content batch-to-batch through Pharmanza's quality control. Standardization enables consistent clinical effects across trials and supports product-line consumer expectations.

5-LOX inhibition mechanism

WokVel®'s boswellic acids selectively inhibit 5-lipoxygenase, reducing leukotriene-mediated inflammation. The non-NSAID mechanism provides anti-inflammatory benefits without GI and cardiovascular concerns of long-term NSAID use.

Joint mobility and quality of life

The one small WokVel crossover trial reported greater knee flexion and longer walking distance in knee osteoarthritis; quality-of-life gains reported for boswellia come from trials of other extracts, not WokVel. Functional findings for WokVel rest on that single small study.

Supported by Trial 1

Boswellia in other conditions (generic gum resin, not WokVel)

Boswellia serrata gum resin has been studied in other inflammatory conditions such as asthma and ulcerative colitis, but those trials used generic gum resin, not WokVel, and do not establish an anti-inflammatory benefit for this branded extract.

Supported by Trial 1

Quality assurance over generic alternatives

Generic boswellia extracts vary significantly in actual boswellic acid content and processing quality. WokVel® addresses this through verified standardization and clinical trial validation. Brand premium reflects quality control investment.

Supported by Trial 1

Mechanism of action

1

5-lipoxygenase pathway inhibition

WokVel® boswellic acids selectively inhibit 5-LOX enzyme, reducing leukotriene production and leukotriene-mediated inflammation. Mechanism distinguishes from NSAIDs (COX inhibition) — different pathway with different safety profile.

2

NF-κB and inflammatory cytokine modulation

Beyond 5-LOX inhibition, boswellic acids modulate NF-κB activation and inflammatory cytokines. Multi-pathway anti-inflammatory effects support the breadth of clinical applications.

3

Cartilage support in osteoarthritis

Boswellic acids act on cartilage-related enzymes in laboratory studies, but no disease-modifying or cartilage-protective effect has been shown for WokVel in people.

Clinical trials

1
Knee osteoarthritis crossover trial (Kimmatkar 2003, n=30)
PubMed

Randomized double-blind placebo-controlled crossover trial of a Pharmanza Boswellia serrata extract in knee osteoarthritis (Kimmatkar 2003, n=30, 8 weeks per arm).

30 adults with knee osteoarthritis (Kimmatkar 2003).

One small randomized double-blind placebo-controlled crossover trial of a Pharmanza Boswellia serrata extract (Kimmatkar 2003, 30 knee osteoarthritis patients, 8 weeks per arm) found less knee pain and swelling, greater knee flexion and longer walking distance versus placebo. It is the main WokVel-specific human trial and is small and old.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated across clinical trial use.
Mild GI discomfort possible at higher doses.
No significant cardiovascular or hepatic concerns documented.
Long-term safety beyond a few weeks is not established: the WokVel-specific trial lasted 8 weeks per arm.
Pregnant and lactating women should consult healthcare providers.

Important Drug interactions

Generally minimal drug interactions documented.
Theoretical caution with anticoagulants through mild anti-inflammatory effects.
Possible additive effects with other anti-inflammatory supplements (curcumin, fish oil).
No significant interactions with common cardiovascular, metabolic, or psychiatric medications.
Consult healthcare providers when combining with IBD medications or DMARDs.

More Joint Health Ingredients

Joint Health
Boswellia Serrata
Boswellia Serrata is a resin extract from the boswellia tree (Indian frankincense) used in…
Joint Health
Casperome® (Boswellia Phytosome — Indena)
Casperome® is Indena's phytosome-formulated Boswellia serrata extract — addressing the maj…
Joint Health
Boswellin® / Boswellin® Super (Standardized Boswellia serrata — Sabinsa)
Boswellin® is Sabinsa's branded Boswellia serrata gum resin extract, available in multiple…
Joint Health
SAMe (S-Adenosyl-L-Methionine)
S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized…

Explore Other Ingredients

Sleep Health
Serezin™
Serezin™ is PLT Health Solutions' patented blend of Boswellia serrata and ginger (Zingiber…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Antioxidant
Curcumin/Turmeric
Curcumin, the primary bioactive compound in turmeric (Curcuma longa), is commonly suppleme…

Frequently asked questions about WokVel® (Boswellia Serrata Extract — Pharmanza)

What is WokVel?

WokVel® is the branded standardized boswellia serrata extract from Pharmanza Herbal (India) — a boswellia form whose own clinical testing is limited to one small, older placebo-controlled knee osteoarthritis trial; the broader boswellia research for joint and inflammatory conditions comes mostly from other extracts and…

What is WokVel used for?

WokVel is researched primarily for Joint Health. A single small randomized crossover trial of a Pharmanza Boswellia serrata extract (Kimmatkar 2003, 30 knee osteoarthritis patients, 8 weeks per arm) reported reduced knee pain and improved function.

What is the recommended dosage of WokVel?

The clinically studied dose is 333 mg three times daily (1,000 mg/day total) or equivalent split doses. Always follow the product label and check with a healthcare provider for personal advice.

Is WokVel safe, and does it have side effects?

For most healthy adults, WokVel is well tolerated at studied doses. Reported effects can include: Generally well-tolerated across clinical trial use. Mild GI discomfort possible at higher doses. It may also interact with some medications. WokVel is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does WokVel interact with any medications?

Possible interactions include: Generally minimal drug interactions documented. Theoretical caution with anticoagulants through mild anti-inflammatory effects. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for WokVel?

NutraSmarts rates the evidence for WokVel as Limited (2 out of 5). It is backed by 1 clinical trial and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Majeed M, Majeed S, Narayanan NK, Nagabhushanam K. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019;33(5):1457-1468. doi: 10.1002/ptr.6338.PubMedUsed to support: Small (n=48), 120-day industry-funded RCT of Boswellin, a Boswellia serrata extract made by Sami Labs/Sabinsa, in knee osteoarthritis: it reduced WOMAC pain and stiffness and serum hs-CRP versus placebo. This is a different branded extract than WokVel, so it supports boswellia for knee osteoarthritis generally, not WokVel specifically.
  2. Majeed A, Majeed S, Satish G, Manjunatha R, Rabbani SN, Patil NVP, et al. A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial. Front Pharmacol. 2024;15:1428440. doi: 10.3389/fphar.2024.1428440.PubMedUsed to support: Three-arm placebo-controlled RCT (105 randomized) of Boswellin Super, a Sami-Sabinsa Boswellia serrata extract standardized to 30% AKBA, in knee osteoarthritis: pain and WOMAC scores improved (early changes by day 5) and TNF-alpha, IL-6 and hs-CRP fell. This is a competitor's branded extract, not WokVel, so it is class evidence for boswellia rather than evidence for WokVel.
  3. Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998;3(11):511-4.PubMedUsed to support: Small (n=40), 6-week double-blind placebo-controlled trial of generic Boswellia serrata gum resin in bronchial asthma, with more patients improving on boswellia than placebo. This is a different condition and a generic gum resin, not WokVel and not a joint outcome.
  4. Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2(1):37-43.PubMedUsed to support: Small (n=42) trial of generic Boswellia serrata gum resin in ulcerative colitis reporting remission rates similar to sulfasalazine, but it was open-label with no placebo control. This is a different condition and a generic gum resin, not WokVel and not a joint outcome.
  5. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine. 2003;10(1):3-7. doi: 10.1078/094471103321648593.PubMedUsed to support: Small (n=30), 8-week randomized double-blind placebo-controlled crossover trial of a Pharmanza Boswellia serrata extract (the form marketed as WokVel; co-author L. Hingorani is affiliated with Pharmanza Herbal) in knee osteoarthritis: active treatment reduced knee pain and swelling and increased knee flexion and walking distance versus placebo, with no radiological change. This is the main WokVel-specific human trial, and it is small, old and used a crossover design.
  6. Kulkarni PD, Damle ND, Singh S, Yadav KS, Ghante MR, Bhaskar VH, Hingorani L, Gota VS. Double-blind trial of solid lipid Boswellia serrata particles (SLBSP) vs. standardized Boswellia serrata gum extract (BSE) for osteoarthritis of knee. Drug Metab Pers Ther. 2020;35(2):dmpt-2020-0104. doi: 10.1515/dmpt-2020-0104.PubMedUsed to support: Randomized, double-blind, double-dummy trial from Pharmanza in knee osteoarthritis comparing a solid-lipid Boswellia particle formulation with a standardized Boswellia serrata gum extract: WOMAC and VAS pain scores improved in both arms with no significant difference between them. Pro-inflammatory cytokines fell in the solid-lipid arm but rose several-fold in the standard-extract arm. It supports Pharmanza boswellia for knee osteoarthritis but has no pure-placebo efficacy arm.